Utilizing our proprietary selective translation regulation technology platform, we have developed an understanding of genes that are translationally upregulated in multiple tumor types. This has enabled us to identify specific points of therapeutic intervention that may have a meaningful clinical effect. We believe our in-depth understanding of translation regulation biology combined with our sophisticated structure-based design approach to medicinal chemistry has given us a key advantage in pioneering the emerging field of translation regulation therapeutics and creating significant barriers to entry.
Certain RNA viruses, including SARS-CoV-2, the causative agent of COVID-19, hijack the host cell translational machinery to drive viral replication. Because of this, we are planning to test one of our STRIs, zotatifin, in patients with mild-to-moderate COVID 19.
eFFECTOR was founded on pioneering research in the laboratories of Drs. Davide Ruggero and Kevan Shokat and subsequently licensed proprietary applications of translational profiling technology from the University of California, San Francisco. The company’s scientific founders and management team comprise industry veterans who have played important roles in the discovery and development of marketed small molecule drugs, monoclonal antibody therapeutics and cellular immunotherapies in oncology and other disease areas.